BDSX
Biodesix·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BDSX
Biodesix, Inc.
A leading data-driven diagnostic solutions company with a focus in lung disease
919 West Dillon Rd., Louisville, CO 80027
--
Biodesix, Inc., was founded in Delaware in 2005. The company is a leading data-driven diagnostic solutions company that leverages its proprietary artificial intelligence (AI) platform to discover, develop and commercialize solutions for clinical unmet needs, focusing on lung diseases.
Earnings Call
Q3/2025
Estimate EPS-1.51
Actual EPS-1.16
Estimate Revenue20.98M
Actual Revenue21.80M
Biodesix's Q3 2025 Earnings Call: Emerging Contradictions in Primary Care Strategy, Sales Rep Productivity, Medicare Payments, and Pipeline Expansion
Nov 03,2025 10:53
Earnings Decrypt
Earnings Decrypt
Q1/2025
Estimate EPS--
Actual EPS-0.08
Estimate Revenue19.50M
Actual Revenue17.96M
Biodesix's Q1 2025: Unraveling Contradictions in Sales Strategy, EBITDA Targets, and Revenue Growth
May 20,2025 11:53
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BDSX has released its 2025 Q3 earnings. EPS was reported at -1.16, versus the expected -1.51, beating expectations. The chart below visualizes how BDSX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BDSX has released its 2025 Q3 earnings report, with revenue of 21.77M, reflecting a YoY change of 19.93%, and net profit of -8.72M, showing a YoY change of 15.03%. The Sankey diagram below clearly presents BDSX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
